EUVIMEDEUVIMED entdecken
Crossref

Verapamil Modulates Activity of Antimicrobials Against Rapidly Growing Mycobacteria

Andressa Araújo Machado do Nascimento, Carolina Trevisolli Palomo, Regiane Bertin de Lima Scodro, Katiany Rizzieri Caleffi-Ferracioli, Vera Lucia Dias Siqueira iD, Jean Eduardo Meneguello iD, Rosilene Fressatti Cardoso

Microbial Drug Resistance · 2025

DOI: 10.1089/mdr.2024.0116 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Microbial Drug Resistance, 2025. Verfasst von Andressa Araújo Machado do Nascimento und 6 weiteren Autor:innen. Beteiligte Einrichtung: Graduate Program in Biosciences and Physiopathology, State University Maringá, Maringá, Brazil. Hauptthemen laut MEDLINE: Nontuberculous Mycobacteria, Verapamil, Anti-Bacterial Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 22 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rapidly growing mycobacteria (RGM) have been causing diseases with an increasing incidence that require long and difficult treatment. In this regard, it is a priority to seek rapid and low-cost optimization of therapeutic alternatives. Thus, our objective is to explore the combined activity between verapamil (VP) and the antimicrobials clarithromycin, amikacin, and clofazimine (CFZ) against Mycobacterium smegmatis , Mycobacterium abscessus subsp. abscessus , Mycobacterium abscessus subsp. massiliense , Mycobacterium abscessus subsp. bolletii , Mycobacterium chelonae , and Mycobacterium fortuitum . According to the checkerboard assay, it was observed that the best combination was between VP and CFZ, with synergistic activity on all tested bacteria. The time-killing assay demonstrated that VP improved the killing of CFZ and extended its inhibitory activity 16 times. In this sense, VP has modulating activity with most of the tested antimicrobials, especially with CFZ, and thus may have potential activity in preventing bacterial resistance that could be pointed out as a model for synergism in attempts at screening molecules for RGM infection treatments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Nontuberculous MycobacteriaVerapamilAnti-Bacterial AgentsMicrobial Sensitivity TestsDrug SynergismClarithromycinAmikacinClofazimineMycobacterium Infections, Nontuberculous

Stichwörter der Autor:innen

rapidly growing mycobacteriasynergismtreatmentverapamil

Substanzen

VerapamilClarithromycinAnti-Bacterial AgentsAmikacinClofazimine

Autor:innen und Institutionen

  • Graduate Program in Biosciences and Physiopathology, State University Maringá, Maringá, Brazil.
  • Graduate Program in Health Sciences, State University Maringá, Maringá, Brazil.

ORCID-Profile: Vera Lucia Dias Siqueira, Jean Eduardo Meneguello

Zitieren

APA

Machado do Nascimento, A. A., Palomo, C. T., Scodro, R. B. L., Caleffi-Ferracioli, K. R., Siqueira, V. L. D., Meneguello, J. E., & Cardoso, R. F. (2025). Verapamil Modulates Activity of Antimicrobials Against Rapidly Growing Mycobacteria. Microbial Drug Resistance. https://doi.org/10.1089/mdr.2024.0116

Vancouver

Machado do Nascimento AA, Palomo CT, Scodro RBL, Caleffi-Ferracioli KR, Siqueira VLD, Meneguello JE, et al. Verapamil Modulates Activity of Antimicrobials Against Rapidly Growing Mycobacteria. Microbial Drug Resistance. 2025. doi:10.1089/mdr.2024.0116

BibTeX
@article{MachadodoNascimento2025,
  author = {Machado do Nascimento, Andressa Araújo and Palomo, Carolina Trevisolli and Scodro, Regiane Bertin de Lima and Caleffi-Ferracioli, Katiany Rizzieri and Siqueira, Vera Lucia Dias and Meneguello, Jean Eduardo and Cardoso, Rosilene Fressatti},
  title = {Verapamil Modulates Activity of Antimicrobials Against Rapidly Growing Mycobacteria},
  journal = {Microbial Drug Resistance},
  year = {2025},
  doi = {10.1089/mdr.2024.0116}
}
Kostenlos starten →